SAN DIEGO--(BUSINESS WIRE)--Sevion Therapeutics, Inc. (“Sevion” or the “Company”)(OTCBB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, MD, PhD, Chief Scientific Officer, gave an oral presentation on the company’s cow-derived ultralong CDR3 antibody platform and an update on SVN-001, its antibody targeting the ion channel Kv1.3 for autoimmune diseases, at the international PEGS conference in Boston, MA on May 4, 2015. “
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
